Involvement of neuropeptide systems in schizophrenia: human studies.

Involvement of neuropeptide systems in schizophrenia: human studies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Involvement of neuropeptide systems in schizophrenia: human studies. Abstract Text:

Ricardo ,Becky Kinkead,Charles B Nemeroff,

Involvement of neuropeptide systems in schizophrenia: human studies. Publishing Authors By Initials

R ,B Kinkead,CB Nemeroff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Involvement of neuropeptide systems in schizophrenia: human studies. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International review of neurobiology

VOLUME: 78

Page Numbers: 327-76

Journal Abbreviation: Int. Rev. Neurobiol.

ISSN: 0074-7742

DAY: 12

MONTH: 03

YEAR: 2007

Involvement of neuropeptide systems in schizophrenia: human studies. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374740

Involvement of neuropeptide systems in schizophrenia: human studies. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Involvement of neuropeptide systems in schizophrenia: human studies. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Involvement of neuropeptide systems in schizophrenia: human studies.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine Atlanta, Georgia 30322, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int Rev Neurobiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Involvement of neuropeptide systems in schizophrenia: human studies Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.